Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYRX CryoPort	$7.64 +2.7%	$6.54	$4.58 ▼ $9.78	$384.05M	1.89	512,764 shs	190,914 shs
DRNA Dicerna Pharmaceuticals	$38.22	$38.12	$19.06 ▼ $40.14	$2.99B	0.8	1.34 million shs	N/A
PBH Prestige Consumer Healthcare	$79.98 -0.2%	$84.18	$64.94 ▼ $90.04	$3.95B	0.43	306,011 shs	243,045 shs
RCUS Arcus Biosciences	$8.47 -1.5%	$8.83	$6.50 ▼ $18.98	$896.85M	0.8	879,840 shs	297,205 shs
ZNTL Zentalis Pharmaceuticals	$1.25 +0.8%	$1.32	$1.01 ▼ $5.44	$90.66M	1.59	1.45 million shs	384,919 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYRX CryoPort	+2.69%	+4.80%	+30.82%	+43.07%	+22.04%
DRNA Dicerna Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
PBH Prestige Consumer Healthcare	-0.20%	-1.48%	-5.89%	-3.46%	+19.00%
RCUS Arcus Biosciences	-1.46%	-0.70%	-15.60%	+23.22%	-41.05%
ZNTL Zentalis Pharmaceuticals	+0.81%	-0.79%	-8.09%	+6.84%	-64.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYRX CryoPort	2.1799 of 5 stars	3.4	2.0	0.0	0.0	2.1	2.5	0.0
DRNA Dicerna Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	4.4677 of 5 stars	2.3	4.0	1.7	3.5	2.9	1.7	1.9
RCUS Arcus Biosciences	2.8568 of 5 stars	4.4	3.0	0.0	0.0	0.9	1.7	0.0
ZNTL Zentalis Pharmaceuticals	1.5997 of 5 stars	3.3	2.0	0.0	0.0	0.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYRX CryoPort	2.71	Moderate Buy	$11.00	43.98% Upside
DRNA Dicerna Pharmaceuticals	0.00	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	2.50	Moderate Buy	$93.33	16.70% Upside
RCUS Arcus Biosciences	2.89	Moderate Buy	$21.29	151.46% Upside
ZNTL Zentalis Pharmaceuticals	2.50	Moderate Buy	$8.37	569.33% Upside

Current Analyst Ratings Breakdown

Latest DRNA, PBH, ZNTL, RCUS, and CYRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	ZNTL Zentalis Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00
5/15/2025	ZNTL Zentalis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	CYRX CryoPort	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
5/8/2025	PBH Prestige Consumer Healthcare	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00
5/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $26.00
5/5/2025	CYRX CryoPort	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $7.00
4/23/2025	RCUS Arcus Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $14.00
4/16/2025	CYRX CryoPort	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYRX CryoPort	$228.38M	1.68	N/A	N/A	$7.44 per share	1.03
DRNA Dicerna Pharmaceuticals	$164.31M	18.17	N/A	N/A	$1.84 per share	20.77
PBH Prestige Consumer Healthcare	$1.14B	3.47	$5.21 per share	15.34	$37.04 per share	2.16
RCUS Arcus Biosciences	$258M	3.47	N/A	N/A	$5.30 per share	1.60
ZNTL Zentalis Pharmaceuticals	$67.43M	1.33	N/A	N/A	$4.73 per share	0.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYRX CryoPort	-$114.76M	-$2.34	N/A	N/A	N/A	-50.15%	-11.03%	-5.54%	8/5/2025 (Estimated)
DRNA Dicerna Pharmaceuticals	-$112.75M	-$1.63	N/A	N/A	N/A	-64.53%	-103.08%	-16.58%	N/A
PBH Prestige Consumer Healthcare	$214.60M	$4.29	18.64	16.80	2.40	18.86%	12.87%	6.78%	8/6/2025 (Estimated)
RCUS Arcus Biosciences	-$283M	-$4.19	N/A	N/A	N/A	-258.94%	-70.58%	-32.97%	8/4/2025 (Estimated)
ZNTL Zentalis Pharmaceuticals	-$165.84M	-$3.13	N/A	N/A	N/A	N/A	-65.48%	-51.05%	8/8/2025 (Estimated)

Latest DRNA, PBH, ZNTL, RCUS, and CYRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ZNTL Zentalis Pharmaceuticals	-$0.67	-$0.67	N/A	-$0.67	N/A	N/A
5/8/2025	Q4 2025	PBH Prestige Consumer Healthcare	$1.30	$1.32	+$0.02	$1.00	$289.36 million	$296.52 million
5/7/2025	Q1 2025	CYRX CryoPort	-$0.23	-$0.22	+$0.01	-$0.28	$56.19 million	$41.04 million
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYRX CryoPort	N/A	N/A	N/A	N/A	N/A
DRNA Dicerna Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYRX CryoPort	0.51	5.56	5.24
DRNA Dicerna Pharmaceuticals	N/A	2.46	2.46
PBH Prestige Consumer Healthcare	0.55	4.20	2.82
RCUS Arcus Biosciences	0.09	5.37	5.37
ZNTL Zentalis Pharmaceuticals	N/A	6.94	6.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYRX CryoPort	92.90%
DRNA Dicerna Pharmaceuticals	78.91%
PBH Prestige Consumer Healthcare	99.95%
RCUS Arcus Biosciences	92.89%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CYRX CryoPort	10.00%
DRNA Dicerna Pharmaceuticals	10.20%
PBH Prestige Consumer Healthcare	1.60%
RCUS Arcus Biosciences	9.60%
ZNTL Zentalis Pharmaceuticals	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYRX CryoPort	1,186	50.14 million	45.12 million	Optionable
DRNA Dicerna Pharmaceuticals	302	78.13 million	70.16 million	Optionable
PBH Prestige Consumer Healthcare	540	49.42 million	48.62 million	Optionable
RCUS Arcus Biosciences	500	105.89 million	95.72 million	Optionable
ZNTL Zentalis Pharmaceuticals	160	71.95 million	70.59 million	Optionable

DRNA, PBH, ZNTL, RCUS, and CYRX Headlines

Recent News About These Companies

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 1 at 5:00 PM | globenewswire.com

Here's Why We're Watching Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

June 26, 2025 | finance.yahoo.com

Zentalis Pharmaceuticals shareholders elect three directors at annual meeting

June 20, 2025 | investing.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Brokerages

June 17, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Bank of America Corp DE

June 10, 2025 | marketbeat.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

May 14, 2025 | globenewswire.com

First Patient Dosed With Azenosertib in Cyclin E1+ Ovarian Cancer

May 3, 2025 | curetoday.comC

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2025 | globenewswire.com

Scott Dunseth Myers Purchases 21,000 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock

May 1, 2025 | insidertrades.com

Zentalis shares insights on cancer research at AACR

April 29, 2025 | investing.com

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

April 28, 2025 | globenewswire.com

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

April 23, 2025 | globenewswire.com

Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 8.97%

April 10, 2025 | aaii.comA

Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 12.58%

April 2, 2025 | aaii.comA

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 1, 2025 | globenewswire.com

Stifel Nicolaus Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)

March 27, 2025 | markets.businessinsider.com

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

March 26, 2025 | globenewswire.com

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

March 25, 2025 | globenewswire.com

Zentalis presents updated clinical data on azenosertib as SGO 2025

March 16, 2025 | markets.businessinsider.com

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

March 15, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRNA, PBH, ZNTL, RCUS, and CYRX Company Descriptions

CryoPort NASDAQ:CYRX

$7.64 +0.20 (+2.69%)

Closing price 07/3/2025 01:29 PM Eastern

Extended Trading

$7.42 -0.22 (-2.81%)

As of 07/3/2025 04:35 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Dicerna Pharmaceuticals NASDAQ:DRNA

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

Prestige Consumer Healthcare NYSE:PBH

$79.98 -0.20 (-0.25%)

Closing price 07/3/2025 03:30 PM Eastern

Extended Trading

$79.82 -0.16 (-0.19%)

As of 07/3/2025 04:20 PM Eastern

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Arcus Biosciences NYSE:RCUS

$8.46 -0.13 (-1.46%)

Closing price 07/3/2025 03:55 PM Eastern

Extended Trading

$8.46 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$1.25 +0.01 (+0.81%)

As of 07/3/2025 02:21 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time